Vital Farms (VITL) 10-Q 9 May 24 2024 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2024	May 06, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Entity Registrant Name	Vital Farms, Inc.
Entity Central Index Key	0001579733
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Security 12b Title	Common Stock, par value $0.0001 per share
Trading Symbol	VITL
Security Exchange Name	NASDAQ
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-39411
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	27-0496985
Entity Address, Address Line One	3601 South Congress Avenue
Entity Address, Address Line Two	Suite C100
Entity Address, City or Town	Austin
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78704
City Area Code	877
Local Phone Number	455-3063
Entity Common Stock, Shares Outstanding		42,176,860

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 113,820	$ 84,149
Investment securities, available-for-sale	23,724	32,667
Accounts receivable, net of allowance for credit losses of $266 and $550 as of March 31, 2024 and December 31, 2023, respectively	43,637	39,699
Inventories	30,813	32,895
Prepaid expenses and other current assets, net of allowance for credit losses of $135 and $227 as of March 31, 2024 and December 31, 2023, respectively	6,176	6,114
Total current assets	218,170	195,524
Property, plant and equipment, net	66,231	66,839
Operating lease right-of-use assets	10,842	8,911
Goodwill and other assets	4,915	3,904
Total assets	300,158	275,178
Current liabilities:
Accounts payable	33,119	33,485
Accrued liabilities	22,280	24,218
Operating lease liabilities, current	4,582	3,057
Finance lease liabilities, current	3,479	3,255
Income taxes payable	6,908	1,206
Total current liabilities	70,368	65,221
Operating lease liabilities, non-current	5,101	5,771
Finance lease liabilities, non-current	10,321	10,481
Other liabilities	1,064	1,028
Total liabilities	86,854	82,501
Commitments and contingencies (Note 18)
Stockholders’ equity:
Preferred stock, $0.0001 par value per share, 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value per share, 310,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 42,003,656 and 41,684,649 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	4	4
Additional paid-in capital	164,821	163,325
Retained earnings	48,748	29,725
Accumulated other comprehensive loss	(269)	(377)
Total stockholders’ equity	213,304	192,677
Total liabilities and stockholders' equity	$ 300,158	$ 275,178

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Accounts Receivable, net of allowance for credit losses	$ 266	$ 550
Prepaid expenses and other current assets, net of allowance for credit losses	$ 135	$ 227
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	310,000,000	310,000,000
Common stock, shares issued	42,003,656	41,684,649
Common stock, shares outstanding	42,003,656	41,684,649

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 26, 2023
Income Statement [Abstract]
Net revenue	$ 147,929	$ 119,172
Cost of goods sold	89,032	76,504
Gross profit	58,897	42,668
Operating expenses:
Selling, general and administrative	27,132	23,946
Shipping and distribution	7,596	7,826
Total operating expenses	34,728	31,772
Income from operations	24,169	10,896
Other income (expense), net:
Interest expense	(255)	(139)
Interest income	1,088	340
Other expense, net	(277)	(1,425)
Total other income (expense), net	556	(1,224)
Net income before income taxes	24,725	9,672
Income tax provision	5,702	2,522
Net income	$ 19,023	$ 7,150
Net income per share:
Basic:	$ 0.46	$ 0.18
Diluted:	$ 0.43	$ 0.16
Weighted average common shares outstanding:
Basic:	41,792,527	40,764,546
Diluted:	43,845,952	43,398,336

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 26, 2023
Statement of Comprehensive Income [Abstract]
Net income	$ 19,023	$ 7,150
Other comprehensive income, before tax:
Unrealized net holding gain	144	517
Amounts reclassified for realized (losses) gains to earnings	(1)	34
Available-for-sale debt securities, before tax	143	551
Other comprehensive income, before tax	143	551
Income tax expense related to items of other comprehensive income	(35)	(130)
Other comprehensive income, net of tax	108	421
Comprehensive income	$ 19,131	$ 7,571

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY(Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Loss
Beginning Balance at Dec. 25, 2022	$ 158,332	$ 4	$ 155,716	$ 4,159	$ (1,547)
Beginning Balance, Shares at Dec. 25, 2022		40,746,990
Vesting of restricted stock units, Shares		127,595
Shares withheld for tax liability on vested restricted stock units, Shares		(35,535)
Stock-based compensation expense	1,627		1,627
Other comprehensive income loss, net	421				421
Net Income (Loss)	7,150			7,150
Ending Balance at Mar. 26, 2023	167,530	$ 4	157,343	11,309	(1,126)
Ending Balance, Shares at Mar. 26, 2023		40,839,050
Beginning Balance at Dec. 31, 2023	$ 192,677	$ 4	163,325	29,725	(377)
Beginning Balance, Shares at Dec. 31, 2023	41,684,649	41,684,649
Exercise of stock options	$ 824		824
Exercise of stock options, Shares	180,086	180,086
Vesting of restricted stock units, Shares		201,702
Shares withheld for tax liability on vested restricted stock units	$ (1,310)		(1,310)
Shares withheld for tax liability on vested restricted stock units, Shares		(62,781)
Stock-based compensation expense	1,982		1,982
Other comprehensive income loss, net	108				108
Net Income (Loss)	19,023			19,023
Ending Balance at Mar. 31, 2024	$ 213,304	$ 4	$ 164,821	$ 48,748	$ (269)
Ending Balance, Shares at Mar. 31, 2024	42,003,656	42,003,656

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 26, 2023
Cash flows from operating activities:
Net income	$ 19,023	$ 7,150
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,297	1,693
Reduction in the carrying amount of right-of-use assets	1,673	793
Amortization of available-for-sale debt securities	65	163
Stock-based compensation expense	1,982	2,241
Deferred taxes	0	445
Net realized losses on derivative instruments	300	1,047
Other	(289)	139
Net change in operating assets and liabilities	(1,102)	(8,268)
Net cash provided by operating activities	23,949	5,403
Cash flows from investing activities:
Purchases of property, plant and equipment	(1,324)	(1,802)
Purchases of derivative instruments	(669)	(220)
Maturities and calls of available-for-sale debt securities	9,020	8,935
Proceeds from the sale of property, plant and equipment	0	1,054
Return of investment in variable interest entity	0	552
Net cash provided by investing activities	7,027	8,519
Cash flows from financing activities:
Proceeds from exercise of stock options	824	0
Payment of tax withholding obligation on vested RSU shares	(1,310)	(614)
Principal payments under finance lease obligations	(819)	(384)
Net cash used in financing activities	(1,305)	(998)
Net increase in cash and cash equivalents	29,671	12,924
Cash and cash equivalents at beginning of the period	84,149	12,914
Cash and cash equivalents at end of the period	113,820	25,838
Supplemental disclosure of cash flow information:
Cash paid for interest	255	134
Cash paid for income taxes	0	2
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property, plant and equipment included in accounts payable and accrued liabilities	623	891
Revolving Line of Credit
Cash flows from financing activities:
Proceeds from borrowing under revolving line of credit	0	7,500
Repayment of revolving line of credit	$ 0	$ (7,500)

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 26, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ 19,023	$ 7,150

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Non Rule 10b51 Arr Modified Flag	false
Rule 10b51 Arr Modified Flag	false

Nature of the Business and Basi

Nature of the Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business and Basis of Presentation	Note 1. Nature of the Business and Basis of Presentation Vital Farms, Inc. (the “Company”) was incorporated in Delaware on June 6, 2013 and is headquartered in Austin, Texas. The Company packages, markets and distributes shell eggs, butter and other products. These products are principally sold under the name Vital Farms in addition to other trade names, primarily to retail and foodservice channels in the United States. The accompanying unaudited condensed consolidated financial statements as of March 31, 2024 and for the 13-week periods ended March 31, 2024 and March 26, 2023 have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP” or “GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Annual Report”). In the opinion of management, the included disclosures are adequate, and the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary for a fair statement of the Company’s consolidated financial position as of March 31, 2024, consolidated results of operations for the 13-week periods ended March 31, 2024 and March 26, 2023, and consolidated cash flows for the 13-week periods ended March 31, 2024 and March 26, 2023. Such adjustments are of a normal and recurring nature and certain reclassifications of previously reported amounts have been made to conform to the current year presentation. The condensed consolidated balance sheet as of December 31, 2023 was derived from audited annual financial statements but does not contain all of the footnote disclosures from the audited annual financial statements. The condensed consolidated results of operations for the 13-week period ended March 31, 2024 are not necessarily indicative of the consolidated results of operations that may be expected for the fiscal year ending December 29, 2024. Fiscal Year: The Company’s fiscal year ends on the last Sunday in December and contains either 52 or 53 weeks. In a 52-week fiscal year, each of the Company’s fiscal quarters consist of 13 weeks. The additional week in a 53-week fiscal year is added to the fourth quarter, making such quarter consist of 14 weeks. Therefore, the financial results of certain 53-week fiscal years, and the associated 14-week quarters, will not be exactly comparable to the prior and subsequent 52-week fiscal years and the associated 13-week quarters. The fiscal quarters ended March 31, 2024 and March 26, 2023 both contain operating results for 13 weeks. The fiscal year ended December 31, 2023 consisted of 53 weeks.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies The significant accounting policies and estimates used in preparation of the unaudited condensed consolidated financial statements are described in the Company’s audited consolidated financial statements as of and for the fiscal year ended December 31, 2023, and the notes thereto, which are included in the Company’s Annual Report. Other than the adoption of the new accounting pronouncements and standards as further described below, there have been no material changes to the Company’s significant accounting policies during the 13-week period ended March 31, 2024. Recently Adopted Accounting Pronouncements The new accounting pronouncements recently adopted by the Company are described in the Company’s audited consolidated financial statements as of and for the fiscal year ended December 31, 2023, and the notes thereto, which are included in the Annual Report. There have been no new accounting pronouncements adopted by the Company during the 13-week period ended March 31, 2024. Recently Issued Accounting Pronouncements Not Yet Adopted In November 2023, the Financial Accounting Standards Board (the “FASB”) issued ASU 2023-07, Segment Reporting (Topic 280) — Improvements to Reportable Segment Disclosures (“ASU 2023-07”) in order to improve stockholders’ understanding of an entity’s business activities through enhanced disclosures around reportable segments. ASU 2023-07 will require incremental and more detailed disclosure regarding segment expenses on both an annual and interim basis. For public companies ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company plans to adopt the standard for the year ended December 29, 2024 and will thus include any additional disclosures, if necessary, in its annual report on Form 10-K for the current fiscal year. In December 2023, the FASB issued ASU No 2023-09, Income Taxes (Topic 740) — Improvements to Income Tax Disclosures (“ASU 2023-09”) in order to enhance the transparency and usefulness of income tax disclosures. The guidance is applicable to all entities subject to income tax and it will require disclosure of certain categories within the rate reconciliation to improve consistency as well as disclosure of reconciling items which meet a certain quantitative threshold which will improve transparency. Additionally, entities must disclose the amount of taxes paid to federal, state and foreign municipalities. For public business entities ASU 2023-09 is effective for annual periods beginning after December 15, 2024. The Company expects to adopt the standard for the fiscal year beginning December 30, 2024. The Company is currently evaluating the impact of its pending adoption of ASU 2023-09 on its consolidated financial statements. In March 2024, the FASB issued ASU No 2024-01, Compensation — Stock Compensation (Topic 718) — Scope Application of Profits Interest and Similar Awards (“ASU 2024-01”) in order to drive consistency across entities in their application of guidance to profits interest and similar types of award grants. ASU 2024-01 seeks to improve consistency through additional examples and illustrations. The guidance is applicable to all entities that account for profits interest awards as compensation to employees or nonemployees and the guidance to be added in paragraph 718-10-15-3 is applicable to all entities that enter into share-based payment transactions. For public business entities ASU 2024-01 is effective for annual periods beginning after December 15, 2024 and interim periods within those annual periods. The Company expects to adopt the standard for the fiscal year beginning December 30, 2024. The Company is currently evaluating the impact of its pending adoption of ASU 2024-01 on its consolidated financial statements.

Investment Securities

Investment Securities	3 Months Ended
	Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]
Investment Securities	Note 3. Investment Securities The following table summarizes the Company’s available-for-sale investment securities as of March 31, 2024: Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Allowance for Credit Losses Fair Value U.S. corporate bonds and U.S. dollar $ 24,047 $ 6 $ ( 329 ) $ — $ 23,724 Total $ 24,047 $ 6 $ ( 329 ) $ — $ 23,724 The following table summarizes the Company’s available-for-sale investment securities as of December 31, 2023: Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Allowance for Credit Losses Fair Value U.S. corporate bonds and U.S. dollar $ 33,134 $ 10 $ ( 477 ) $ — $ 32,667 Total $ 33,134 $ 10 $ ( 477 ) $ — $ 32,667 For the 13-week periods ended March 31, 2024 and March 26, 2023 , there were no proceeds from the sale of available-for-sale securities. Actual maturities may differ from contractual maturities because some borrowers have the right to call or prepay obligations with or without call or prepayment penalties. The amortized cost and fair value of the Company’s investments in available-for-sale securities as of March 31, 2024 by contractual maturity are as follows: Amortized Cost Fair Value Due within one year $ 19,064 $ 18,792 Due after one year through five years 4,983 4,932 Total available-for-sale $ 24,047 $ 23,724 The following tables present the Company ’s unrealized loss aging for available-for-sale securities by type and length of time the security was in a continuous unrealized loss position as of the periods presented: March 31, 2024 Less than 12 months 12 months or longer Total Fair Value Unrealized Losses Fair Value Unrealized Losses Fair Value Unrealized Losses U.S. corporate bonds and U.S. dollar $ 2,397 $ ( 10 ) $ 20,315 $ ( 319 ) $ 22,712 $ ( 329 ) Total $ 2,397 $ ( 10 ) $ 20,315 $ ( 319 ) $ 22,712 $ ( 329 ) December 31, 2023 Less than 12 months 12 months or longer Total Fair Value Unrealized Losses Fair Value Unrealized Losses Fair Value Unrealized Losses U.S. corporate bonds and U.S. dollar $ 699 $ ( 3 ) $ 29,247 $ ( 474 ) $ 29,946 $ ( 477 ) Total $ 699 $ ( 3 ) $ 29,247 $ ( 474 ) $ 29,946 $ ( 477 ) As of March 31, 2024 , there were 38 diversified issuances in the Company's securities portfolio in an unrealized loss position, with credit ratings ranging from BBB- to AA-. As of March 31, 2024, there are no individual bonds with unrealized losses exceeding $ 37 , and 35 issuances have been in a loss position greater than 12 months. The decline in fair value has resulted primarily from rising interest rates over the last 12 months, and the Company does not believe there has been any significant decline in the creditworthiness of the issuers. The Company also does not believe it is likely that a significant number of bonds will be called early, and it does not have current liquidity needs that would necessitate a sale of any material investments prior to maturity. Therefore, the Company has no t recorded an allowance for credit losses on the investment securities as of March 31, 2024. The fair value and location of all investment securities are included in “Fair Value Measurements” in Note 5 below.

Derivative Financial Instrument

Derivative Financial Instruments	3 Months Ended
	Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	Note 4. Derivative Financial Instruments The Company enters into derivative instruments to mitigate the impact of commodity price volatility. Such instruments may include call options on commodity price contracts. Realized and unrealized gains and losses on the Company’s commodity derivatives not designated as hedging instruments are recorded in other expense, net. The Company recognizes all derivative instruments as either assets or liabilities. The following table presents the aggregated outstanding notional amounts related to the Company’s derivative financial instruments for the periods presented: Metric March 31, December 31, Commodity: Corn Bushels (in thousands) 1,629 2,351 Soybean Meal Tons 17 25 For the 13-week periods ended March 31, 2024 and March 26, 2023, the pre-tax amount of commodity contract derivative losses recognized in other expense, net was $ 300 and $ 1,415 , respectively. The fair value and location of all outstanding derivative financial instruments are included in “Fair Value Measurements” in Note 5 below.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 5. Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The three levels of inputs that may be used to measure fair value are defined below: • Level 1 – Quoted prices in active markets for identical assets or liabilities. • Level 2 – Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 – Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. Assets Measured at Fair Value on a Recurring Basis The fair value hierarchy requires the use of observable market data when available. In instances where the inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement has been determined based on the lowest level input significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability. The following tables present information about the Company’s financial assets measured at fair value on a recurring basis for the periods presented: Fair Value Measurements as of March 31, 2024, Using: Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents: Money market $ 92,104 $ — $ — $ 92,104 Investment securities, available-for-sale: U.S. corporate bonds and U.S. dollar — 23,724 — 23,724 Prepaid expenses and other current assets: Derivative financial instruments — 93 — 93 Total assets measured at fair value $ 92,104 $ 23,817 $ — $ 115,921 Fair Value Measurements as of December 31, 2023, Using: Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents: Money market $ 64,498 $ — $ — $ 64,498 Investment securities, available-for-sale: U.S. corporate bonds and U.S. dollar — 32,667 — 32,667 U.S. Treasury — 394 — 394 Total assets measured at fair value $ 64,498 $ 33,061 $ — $ 97,559 During the 13-week period ended March 31, 2024 , there were no transfers between fair value measurement levels. For additional information on concentrations of credit risk for the Company ’s financial instruments, refer to “Investment Securities” in Note 3. Fair Value of Other Financial Instruments The carrying values of the Company’s short-term financial instruments not included above, including cash, trade receivables, other receivables and accounts payable, approximate their fair value due to their short-term nature.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Note 6. Revenue Recognition The following table summarizes the Company’s net revenue by primary product for the periods presented: 13-Weeks Ended March 31, March 26, Net Revenue: Eggs and egg-related products $ 143,761 $ 112,790 Butter and butter-related products 4,168 6,382 Net Revenue $ 147,929 $ 119,172 Net revenue is primarily generated from the sale of eggs and butter. The Company’s product offerings include shell eggs, hard-boiled eggs, liquid whole eggs and stick butter. The Company’s previous convenient breakfast product line (including egg bites and egg-based breakfast bars) was discontinued in 2022, and the Company’s ghee and spreadable tub butter product offerings were discontinued during the fiscal year ended December 31, 2023. The revenues related to the discontinued product lines were immaterial for the 13-week periods ended March 31, 2024 and March 26, 2023. During the 13-week periods ended March 31, 2024 and March 26, 2023 , the Company had a customer that individually exceeded 10% or more of the Company’s net revenue. The percentage of net revenue from significant customers during the 13-week periods ended March 31, 2024 and March 26, 2023 is as follows: Net Revenue Net Revenue Customer A 24 % 25 % Customer B * * Customer C * * Customer D * * * Revenue was less than 10% As of March 31, 2024 and December 31, 2023, the Company had customers that individually exceeded 10% or more of the Company’s accounts receivable. The percentage of accounts receivable, net due from significant customers as of March 31, 2024 and December 31, 2023 is as follows: Accounts Receivable, Net as of March 31, 2024 Accounts Receivable, Net as of December 31, 2023 Customer A 20 % 18 % Customer B 12 % 12 % Customer C * 11 % Customer D 12 % 11 % * Accounts receivable, net was less than 10%

Allowance for Credit Losses

Allowance for Credit Losses	3 Months Ended
	Mar. 31, 2024
Allowance for Credit Loss [Abstract]
Allowance for Credit Losses	Note 7. Allowance for Credit Losses As of March 31, 2024 and December 31, 2023, the Company had an allowance for credit losses of $ 401 and $ 777 , respectively. The Company recognizes current estimated credit losses (“CECL”) for accounts receivable and other receivables. The CECL for trade receivables are estimated based on the trade receivable aging category, credit risk of specific customers, past collection history, and management’s evaluation of accounts receivable. The Company also has other receivables which are classified within prepaid expenses and other current assets. The CECL for other receivables are estimated based on the other receivables aging category and the probability of default. Provisions for CECL are classified within selling, general and administrative costs Changes in the allowance for credit losses for the 13-week period ended March 31, 2024 were as follows: Accounts Receivable Prepaid Expenses and other Current Assets Total As of December 31, 2023 $ ( 550 ) $ ( 227 ) $ ( 777 ) Provisions charged to operating results 284 ( 48 ) 236 Account write-offs — 140 140 As of March 31, 2024 $ ( 266 ) $ ( 135 ) $ ( 401 )

Inventories

Inventories	3 Months Ended
	Mar. 31, 2024
Inventory Disclosure [Abstract]
Inventories	Note 8. Inventories Inventory consisted of the following as of the periods presented: March 31, December 31, Eggs and egg-related products $ 21,346 $ 25,521 Butter and butter-related products 5,084 1,697 Packaging 3,672 4,988 Pullets 221 289 Other 936 896 Reserve for inventory obsolescence ( 446 ) ( 496 ) Inventories $ 30,813 $ 32,895 On a periodic basis, the Company compares the amount of inventory on hand with its latest forecasted requirements to determine whether provisions for excess or obsolete inventory reserves are required.

Property, Plant and Equipment

Property, Plant and Equipment	3 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Note 9. Property, Plant and Equipment Property, plant and equipment consisted of the following as of the periods presented: March 31, December 31, Land $ 552 $ 552 Land improvements 818 818 Buildings and improvements 30,532 30,532 Vehicles 1,055 1,055 Machinery and equipment 54,355 50,979 Leasehold improvements 491 492 Furniture and fixtures 479 461 Construction in progress 2,211 3,001 90,493 87,890 Less: Accumulated depreciation and amortization ( 24,262 ) ( 21,051 ) Property, plant and equipment, net $ 66,231 $ 66,839 During the 13-week periods ended March 31, 2024 and March 26, 2023, depreciation and amortization of property, plant and equipment was approximately $ 2,297 and $ 1,693 , respectively.

Leases

Leases	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Leases	Note 10. Leases Operating lease cost is recognized on a straight-line basis over the lease term and finance lease cost is recognized as amortization expense for the right-of-use (“ROU”) assets and interest expense associated with the finance lease liabilities. The components of lease cost, classified within cost of goods sold, selling, general and administrative and interest expense for the 13-week periods ended March 31, 2024 and March 26, 2023 are below: 13-Weeks Ended March 31, March 26, Operating lease cost $ 922 $ 361 Finance lease cost – amortization of right-of-use assets 914 447 Finance lease cost – interest on lease liabilities 246 132 Short-term lease cost 32 117 Variable lease cost 2,507 1,563 Variable lease cost – long-term supply contracts 25,340 43,086 Total lease cost $ 29,961 $ 45,706 Future undiscounted cash flows are as follows: As of March 31, 2024 Operating Leases Finance Leases 2024 $ 4,227 $ 3,238 2025 3,234 4,356 2026 3,018 4,387 2027 — 3,611 2028 — — Thereafter — — Total lease payments 10,479 15,592 Less imputed interest ( 796 ) ( 1,792 ) Total present value of lease liabilities $ 9,683 $ 13,800 During the 13-week periods ended March 31, 2024 and March 26, 2023, ROU assets obtained in exchange for new finance lease obligations were $ 907 and $ 4 , respectively. During the 13-week periods ended March 31, 2024 and March 26, 2023, ROU assets obtained in exchange for new operating lease obligations were $ 2,489 and $ 0 , respectively.

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
Accrued Liabilities	Note 11. Accrued Liabilities Accrued liabilities consisted of the following as of the periods presented: March 31, December 31, Employee-related costs $ 4,788 $ 9,131 Promotions and customer deductions 6,858 6,982 Distribution fees and freight 3,087 2,876 Marketing and broker commissions 3,113 3,627 Purchases of inventory 2,000 525 Professional fees 2,108 1,066 Other 326 11 Accrued liabilities $ 22,280 $ 24,218

Long-Term Debt

Long-Term Debt	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Long-Term Debt	Note 12. Long-Term Debt In October 2017, the Company entered into a credit facility agreement with PNC Bank, National Association (the “PNC Credit Facility”) that initially included a $ 4.7 million term a loan, a $ 10.0 million revolving line of credit and an equipment loan with a maximum borrowing capacity of $ 1.5 million. Subsequently, the terms of the PNC Credit Facility were modified at various times between fiscal 2018 and fiscal 2022. Such amendments (i) amended various definitions, (ii) waived a technical default in May 2020 which was triggered by exceeding the capital expenditure limit, (iii) increased borrowing capacity and (iv) extended the maturity date. The Ninth Amendment to the PNC Credit Facility in April 2021 eliminated the term loan and equipment loan. The Tenth Amendment to the PNC Credit Facility in December 2022 modified certain covenants related to commodity hedging, provided consent for the dissolution of immaterial subsidiaries and implemented changes related to the discontinuation of LIBOR. The Eleventh Amendment to the PNC Credit Facility, effective July 26, 2023 extended the maturity date by one year, to April 2, 2025 . The maximum borrowing capacity under the revolving line of credit was $ 20.0 million as of March 31, 2024. Interest on borrowings under the revolving line of credit, as well as loan advances thereunder, accrued at a rate, at the Company’s election at the time of borrowing, equal to (i) the secured overnight financing rate as administered by the Federal Reserve Bank of New York plus 2.00 % or (ii) 1.00 % plus the alternate base rate, as defined in the PNC Credit Facility. During the 13-week period ended March 26, 2023, the Company borrowed and repaid $ 7.5 million under the PNC Credit Facility ’s revolving line of credit. As of March 31, 2024 , there were no outstanding amounts under the PNC Credit Facility ’s revolving line of credit. The PNC Credit Facility was secured by all of the Company’s assets (other than real property and certain other property excluded pursuant to the terms of the PNC Credit Facility) and required the Company to maintain three financial covenants: a fixed charge coverage ratio, a leverage ratio and a minimum tangible net worth requirement. The PNC Credit Facility also contained various covenants relating to limitations on indebtedness, acquisitions, mergers, consolidations and the sale of properties and liens. As a result of the limitations contained in the PNC Credit Facility, certain of the net assets on the Company’s consolidated balance sheet as of March 31, 2024 are restricted in use. The Company’s wholly owned subsidiaries are non-operating and have no restricted net assets within the meaning of Rule 4-08(e)(3) or Rule 12-04 of Regulation S-X. The PNC Credit Facility also contained other customary covenants, representations and events of default. As of March 31, 2024 , the Company was in compliance with all covenants under the PNC Credit Facility. During the 13-week periods ended March 31, 2024 and March 26, 2023, the Company recognized interest expense related to draws on the revolving line of credit of $ 0 and $ 7 , respectively. On April 9, 2024, the Company entered into a syndicated credit agreement with JPMorgan Chase Bank, N.A. and the other lenders party thereto (the “JPMorgan Credit Facility” ), which provides for a five-year, $ 60.0 million revolving credit facility. The JPMorgan Credit Facility replaced the PNC Credit Facility , which terminated concurrently with the establishment of the JPMorgan Credit Facility. The JPMorgan Credit Facility includes a $ 5.0 million letter of credit sub-limit and an accordion option which would allow the Company to increase the aggregate revolving commitments or add incremental term loans in an aggregate amount not to exceed the greater of (i) $ 35.0 million and (ii) an amount equal to 100 % of consolidated adjusted EBITDA. Any borrowings under the JPMorgan Credit Facility bear interest, at the Company ’ s election, at either (i) an adjusted term Secured Overnight Financing Rate or adjusted daily Secured Overnight Financing Rate plus 0.10 % plus a margin of either 0.75%, 1.00% or 1.25% depending on the Company ’s net leverage ratio, or (ii) an alternative base rate plus a margin or either 1.75%, 2.00% or 2.25%, depending on the Company’s net leverage ratio. The Company is required to pay a commitment fee on the undrawn portion of the aggregate commitments that accrues at either 0.20% or 0.375% per annum depending on the Company’ s revolving exposure. Additionally, the Company is required to pay a participation fee on the account of each lender for each outstanding letter of credit at a rate equal to the applicable rate used to determine the interest rate applicable to term benchmark revolving loans. The JPMorgan Credit Facility is secured by liens on substantially all of the Company’ s assets, including certain intellectual property assets and investment securities. It requires the Company to maintain (i) a net leverage ratio of no greater than 3.25 to 1.00, subject to two increases up to 4.00 to 1.00 for a certain period following material acquisitions, and (ii) a fixed charge coverage ratio of no less than 1.35 to 1.00.

Common Stock

Common Stock	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Common Stock	Note 13. Common Stock As of March 31, 2024 , the Company’s amended and restated certificate of incorporation authorized the Company to issue 310,000,000 shares of common stock, par value $ 0.0001 per share, of which 42,003,656 shares were issued and outstanding. The voting, dividend and liquidation rights of the holders of the Company’s common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock, if any. Each share of the Company’s common stock is entitled to one vote on all matters submitted to a vote of the Company’s stockholders. Holders of the Company’s common stock are entitled to receive dividends as may be declared by the Company’s Board of Directors, if any, subject to the preferential dividend rights of preferred stock, if any. No cash dividends were declared or paid during the periods presented. As of each balance sheet date, the Company had reserved shares of common stock for issuance in connection with the following: March 31, December 31, Options to purchase common stock 3,722,192 5,123,860 Restricted stock units (“RSUs”) 725,611 675,029 Performance stock units (“PSUs”) 240,072 — Shares available for grant under the 2020 Equity Incentive 14,876,536 12,796,409 Total 19,564,411 18,595,298

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 14. Stock-Based Compensation The Company measures compensation expense for all stock-based awards based on the estimated fair values on the date of the grant. Stock options generally vest ratably over three years from the date of grant and expire 10 years from the date of grant. RSUs generally vest ratably over three years from the date of grant and contain no other service or performance conditions. PSUs vest at the end of a three-year period based on the achievement of certain Company performance metrics and the employee’s continued service over such period. The Company’s policy is to recognize stock-based compensation expense on a straight-line basis over the requisite service or vesting period. For awards that are contingent upon performance metrics, the probability of achievement is taken into account in the calculation of the expense to be recognized and modified as needed. Forfeitures for stock options and restricted stock awards, including RSUs and PSUs , are recognized as they occur. The Company recognized stock-based compensation expense in the condensed consolidated statements of operations for the periods presented: 13-Weeks Ended March 31, March 26, Cost of goods sold $ 47 $ 53 Selling, general and administrative expense 1,935 2,188 Total $ 1,982 $ 2,241 Stock Option Activity The following table summarizes the Company’s stock option activity since December 31, 2023: Number of Weighted- Weighted- Aggregate Outstanding as of December 31, 2023 3,920,485 $ 10.07 $ 28,749 Granted — $ — Exercised ( 180,086 ) $ 4.57 $ 2,402 Cancelled/Forfeited ( 18,207 ) $ 22.45 $ 3 Outstanding as of March 31, 2024 3,722,192 $ 10.27 5.6 $ 50,127 Options exercisable as of March 31, 2024 2,895,661 $ 9.45 5.1 $ 41,438 Options vested and expected to vest as of March 31, 2024 3,722,192 $ 10.27 5.6 $ 50,127 The fair value of stock options vested during the 13-week periods ended March 31, 2024 and March 26, 2023 was $ 1,660 and $ 1,015 , respectively. As of March 31, 2024, total unrecognized stock-based compensation expense related to unvested stock options was $ 2,539 , which is expected to be recognized over a weighted-average period of 1.54 years. Restricted Stock Unit Activity The following table summarizes the Company’s RSU activity since December 31, 2023: Number of Weighted- Unvested as of December 31, 2023 565,376 $ 14.24 Granted 377,352 $ 20.99 Vested 1 ( 201,702 ) $ 14.39 Forfeited ( 15,415 ) $ 15.08 Unvested as of March 31, 2024 725,611 $ 17.69 Includes 62,781 shares of common stock withheld to cover taxes on the release of vested RSUs, which became available for future grants pursuant The fair value of RSU shares vested during the 13-week periods ended March 31, 2024 and March 26, 2023 was $ 2,903 and $ 1,655 , respectively. As of March 31, 2024, total unrecognized stock-based compensation expense related to the RSUs was $ 11,919 , which is expected to be recognized over a weighted-average period of 2.46 years. Performance Stock Unit Activity In fiscal year 2024, the Company granted PSUs to certain of its officers and employees. These PSUs vest at the end of a three-year period dependent upon the level of achievement of certain Company performance metrics and the employee’s continued service over such period. The number of shares that can be earned will range from 0 % to 200 % of the granted PSUs, based upon the Company’s level of achievement of the stated performance metrics. The number of PSUs expected to vest and for which compensation cost has been recognized is based on the number of awards that the Company believes are probable to vest as of March 31, 2024. The following table summarizes the Company’s PSU activity since December 31, 2023: Number of Weighted- Unvested as of December 31, 2023 — Granted 240,072 $ 20.99 Unvested as of March 31, 2024 240,072 $ 20.99 The fair value of PSU shares vested during the 13-week periods ended March 31, 2024 and March 26, 2023 was $ - as no shares have vested as of such periods. As of March 31, 2024, total unrecognized stock-based compensation expense related to the PSUs was $ 9,871 , which is expected to be recognized over a weighted-average period of 2.74 years. 2020 Equity Incentive Plan: In July 2020, the Company’s Board of Directors adopted the 2020 Equity Incentive Plan (“2020 Incentive Plan”), which was subsequently approved by the Company’s stockholders and became effective on July 30, 2020. Initially, the maximum number of the Company’s common stock that may be issued under the 2020 Incentive Plan was 8,595,871 shares. The 2020 Incentive Plan provides that the number of shares reserved and available for issuance under the 2020 Incentive Plan will automatically increase each January 1, beginning on January 1, 2021 and ending on (and including) January 1, 2030, by an amount equal to 4 % of the outstanding number of shares of common stock on the immediately preceding December 31 or such lesser number of shares as determined by the Company’s Board of Directors. As of March 31, 2024, 12,347,296 shares were available for future grants of the Company’s common stock, which includes 1,667,385 shares of stock that were automatically added to the available reserve on January 1, 2024. Awards issued under the 2020 Incentive Plan generally have a three-year ratable vesting period beginning on the date of grant. Employee Stock Purchase Plan: In July 2020, the Company’s Board of Directors adopted the 2020 Employee Stock Purchase Plan (“2020 ESPP”), which was subsequently approved by the Company’s stockholders and became effective on July 30, 2020. The 2020 ESPP authorizes the initial issuance of up to 900,000 shares of the Company’s common stock to eligible employees of the Company or, as designated by the Company’s Board of Directors, employees of a related company. The 2020 ESPP provides that the number of shares reserved and available for issuance under the 2020 ESPP will automatically increase each January 1, beginning on January 1, 2021 and ending on (and including) January 1, 2030, by an amount equal to the lesser of (i) 1 % of the outstanding number of shares of common stock on the immediately preceding December 31 and (ii) 900,000 , or such lesser number of shares as determined by the Company’s Board of Directors. As of March 31, 2024, 2,529,240 shares of the Company’s common stock were available for future issuance under the 2020 ESPP, which includes 416,846 shares of common stock that were automatically added to the available reserve on January 1, 2024. The Company’s Board of Directors authorizes six-month offering periods, with the most recent beginning on November 16, 2023.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Note 15. Income Taxes The Company’s effective tax rate for the 13-week periods ended March 31, 2024 and March 26, 2023 was approximately 23 % and 26 % , respectively. The Company’s effective tax rate for the 13-week period ended March 31, 2024 differs from the statutory rate due primarily to discrete tax benefits related to the exercise of non-qualified stock options and the vesting of restricted stock units. For interim periods, the Company's income tax expense and resulting effective tax rate are based upon an estimated annual effective tax rate adjusted for the effects of items required to be treated as discrete to the period, including changes in tax laws, changes in estimated exposures for uncertain tax positions, and other items. The Company’s estimated annual effective tax rate differs from the federal statutory rate of 21% due to state taxes, permanent differences related to incentive stock options and the impact of compensation deduction limitations under Internal Revenue Code Section 162(m).

Net Income Per Share

Net Income Per Share	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Net Income Per Share	Note 16. Net Income Per Share Basic and diluted net income per share attributable to Vital Farms, Inc. common stockholders were calculated as follows: 13-Weeks Ended March 31, March 26, Numerator: Net income $ 19,023 $ 7,150 Denominator: Weighted average common shares outstanding — basic 41,792,527 40,764,546 Weighted average effect of potentially dilutive securities: Effect of potentially dilutive stock options 1,805,636 2,423,087 Effect of potentially dilutive restricted stock units 241,526 208,947 Effect of potentially dilutive common stock issuable pursuant to the ESPP 6,263 1,756 Weighted average common shares outstanding — diluted 43,845,952 43,398,336 Net income per share attributable to Vital Farms, Inc. stockholders Basic $ 0.46 $ 0.18 Diluted $ 0.43 $ 0.16 The Company excluded the following shares of common stock, outstanding at each period end, from the computation of diluted net income per share attributable to Vital Farms, Inc. common stockholders for the periods indicated because including them would have had an anti-dilutive effect: 13-Weeks Ended March 31, March 26, Options to purchase common stock 37,424 22,363 Unvested RSUs 17,533 704 Unvested PSUs 21,164 — 76,121 23,067

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Accumulated Other Comprehensive Income	Note 17. Accumulated Other Comprehensive Income The amounts reclassified from accumulated other comprehensive income (“AOCI”) to the unaudited consolidated statements of operations were as follows (in thousands): Amounts Reclassified from AOCI 13-Week Period Ended AOCI Component Statement of Income Classification March 31, March 26, Losses on available-for-sale securities Other expense, net $ ( 1 ) $ 34 Total before tax $ ( 1 ) 34 Tax benefit $ — ( 8 ) Net of tax $ ( 1 ) $ 26 The gross amount and related tax (expense) benefit recorded in, and associated with, each component of other comprehensive income were as follows (in thousands): 13-Weeks Ended March 31, 2024 March 26, 2023 Before Tax Tax After Tax Before Tax Tax After Tax Available-for-sale debt securities: Unrealized net holding gain 144 $ ( 35 ) $ 109 $ 517 $ ( 122 ) $ 395 Amounts reclassified for realized losses to earnings ( 1 ) — ( 1 ) 34 ( 8 ) 26 Total other comprehensive income $ 143 $ ( 35 ) $ 108 $ 551 $ ( 130 ) $ 421

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 18. Commitments and Contingencies Supplier Contracts: The Company purchases its egg inventories under long-term supply contracts with farms. Purchase commitments contained in these arrangements are variable and dependent on the quantity of eggs produced by the farms. Accordingly, there are no estimable future purchase commitments associated with these supplier contracts and there are no minimum payments associated with these long-term supply contracts. The Company records the total cost of eggs into inventory and they are expensed to cost of goods sold when the associated eggs are sold to customers and are also reported as part of the Company’s variable lease cost. The Company has entered into agreements with certain qualifying suppliers to provide a one-time payment of $ 200,000 , for the purpose of funding costs associated with farm start up. As of March 31, 2024, the Company has executed 15 such agreements, 2 of which were in fiscal year 2023. The payment of these incremental costs is contingent upon the achievement of certain milestones and is to be made no later than 90 days prior to the pullet placement date specified in each supplier agreement. Upon the achievement of such milestones, the Company recognizes an operating ROU asset and lease liability as a cost of obtaining the embedded lease within the supplier contract, which is included in “Leases” in Note 10. As of March 31, 2024, $ 1.2 million has been paid out and $ 1.8 million remains to be paid. Indemnification Agreements: In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board of Directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. As of March 31, 2024, the Company has not incurred any material costs as a result of such indemnification agreements. Litigation: The Company is subject to various claims and contingencies that are in the scope of ordinary and routine litigation incidental to its business, including those related to regulation, litigation, business transactions, employee-related matters and taxes, among others. When the Company becomes aware of a claim or potential claim, the likelihood of any loss or exposure is assessed. Based on these assessments and estimates, the Company may establish reserves, as appropriate. These assessments and estimates are based on the information available to management at the time and involve a significant amount of management judgment. Actual outcomes or losses may differ materially from the Company’s assessments and estimates. On May 20, 2021, the Company and certain of its current and former officers were named as defendants in a class action complaint captioned Nicholas A. Usler et al. v. Vital Farms, Inc. et al. in the United States District Court for the Western District of Texas. The plaintiffs alleged false advertising claims on behalf of themselves and a putative class of alleged consumers of the Company’s eggs. The named officers of the Company were subsequently dismissed as defendants in this matter. In September 2023, the parties engaged in mediation to discuss potential settlement of remaining claims, but no agreement was reached and the lawsuit is ongoing. The Company believes the claims are without merit and is vigorously defending itself in this matter. Given the uncertainty of the litigation, the stage of the case, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company is unable to reasonably estimate the possible loss or range of loss, if any, that may result from the claim. Although the Company maintains insurance for certain potential liabilities, such insurance does not cover all types and amounts of potential liabilities and is subject to various exclusions and caps on amounts recoverable. Even if the Company believes a claim is covered by insurance, insurers may dispute the Company's entitlement to recovery for a variety of potential reasons, which may affect the timing and, if the insurers prevail, the amount of the Company's recovery. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company records a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, the Company discloses the claim if the likelihood of a potential loss is reasonably possible.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2024
Related Party Transactions [Abstract]
Related Party Transactions	Note 19. Related Party Transactions Sandpebble Builders Preconstruction, Inc.: The Company utilizes Sandpebble Builders Preconstruction, Inc. and Sandpebble South, Inc. (collectively “Sandpebble”) for project management and related services associated with the construction and expansion of the Company’s egg processing facilities, including site selection, project management and related services for the Company’s potential future egg packing facility. The Company’s contract with Sandpebble for services related to the Company’s next egg packing facility was awarded after a competitive bidding process. Victor Canseco, the owner and principal of Sandpebble, is the father of Russell Diez-Canseco, the Company’s President and Chief Executive Officer and a member of the Company’s Board of Directors. In connection with the services described above, the Company paid Sandpebble $ 248 and $ 116 during the 13-week periods ended March 31, 2024 and March 26, 2023, respectively. Amounts paid to Sandpebble are included in property, plant and equipment, net and selling, general and administrative costs. As of March 31, 2024 and March 26, 2023, amounts owed to Sandpebble were $ 313 and $ 373 , respectively, and are included in accrued liabilities.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	Note 20. Subsequent Events Chief Operating Officer Departure On April 3, 2024, the Company entered into a transition agreement (the “COO Transition Agreement”) with Jason Dale, the Company’s Chief Operating Officer and principal operating officer, pursuant to which Mr. Dale will transition into a non-employee advisory role with the Company. The Company is engaged in a search for a Chief Supply Chain Officer (or similarly titled position) to assume certain of Mr. Dale’s responsibilities. Pursuant to the COO Transition Agreement, Mr. Dale will serve as Chief Operating Officer and principal operating officer until the earlier to occur of: (i) the start date of the Company’s Chief Supply Chain Officer (or similarly titled position) or (ii) August 31, 2024 (the “Separation Date”). On August 31, 2024, Mr. Dale will transition to a non-employee advisory role through December 31, 2024 (the “Advisory Period”) to ensure a smooth leadership transition. Prior to the Separation Date, Mr. Dale will continue to receive his current base salary and medical benefits; provided, that Mr. Dale performs such job duties for the Company and assists in such transition-related duties as the Company may deem necessary and appropriate. During the Advisory Period, Mr. Dale will receive a monthly retainer of $ 10,000 and will continue to vest in any equity awards. Upon completion of the Advisory Period, in exchange for a general release of claims in favor of the Company, Mr. Dale will receive severance benefits pursuant to his Second Amended and Restated Employment Agreement, dated as of April 1, 2022, in the form of: (i) 18 months of his annual base salary over the 18-month period following the departure date and (ii) reimbursement of COBRA premiums for a period of up to 12 months. Principal Accounting Officer Departure On April 4, 2024, the Company accepted the resignation of Jeffery Dawson, the Company’s Chief Accounting Officer and principal accounting officer, and entered into a transition agreement, pursuant to which Mr. Dawson transitioned his responsibilities and ceased serving as the Company’s Chief Accounting Officer and principal accounting officer effective April 19, 2024. Thilo Wrede, the Company’s Chief Financial Officer, was designated to serve as the Company’s principal accounting officer following Mr. Dawson’s departure date. The Company has retained a temporary corporate controller and is engaged in a search for a new permanent corporate controller to assume certain of Mr. Dawson’s responsibilities. New Credit Facility On April 9, 2024, the Company entered into the JPMorgan Credit Facility, which provides for a five-year, $ 60.0 million revolving credit facility. The JPMorgan Credit Facility replaced the PNC Credit Facility , which terminated concurrently with the establishment of the JPMorgan Credit Facility. Please see “Long-Term Debt” at Note 12 for further detail on the JPMorgan Credit Facility.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements The new accounting pronouncements recently adopted by the Company are described in the Company’s audited consolidated financial statements as of and for the fiscal year ended December 31, 2023, and the notes thereto, which are included in the Annual Report. There have been no new accounting pronouncements adopted by the Company during the 13-week period ended March 31, 2024.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted In November 2023, the Financial Accounting Standards Board (the “FASB”) issued ASU 2023-07, Segment Reporting (Topic 280) — Improvements to Reportable Segment Disclosures (“ASU 2023-07”) in order to improve stockholders’ understanding of an entity’s business activities through enhanced disclosures around reportable segments. ASU 2023-07 will require incremental and more detailed disclosure regarding segment expenses on both an annual and interim basis. For public companies ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company plans to adopt the standard for the year ended December 29, 2024 and will thus include any additional disclosures, if necessary, in its annual report on Form 10-K for the current fiscal year. In December 2023, the FASB issued ASU No 2023-09, Income Taxes (Topic 740) — Improvements to Income Tax Disclosures (“ASU 2023-09”) in order to enhance the transparency and usefulness of income tax disclosures. The guidance is applicable to all entities subject to income tax and it will require disclosure of certain categories within the rate reconciliation to improve consistency as well as disclosure of reconciling items which meet a certain quantitative threshold which will improve transparency. Additionally, entities must disclose the amount of taxes paid to federal, state and foreign municipalities. For public business entities ASU 2023-09 is effective for annual periods beginning after December 15, 2024. The Company expects to adopt the standard for the fiscal year beginning December 30, 2024. The Company is currently evaluating the impact of its pending adoption of ASU 2023-09 on its consolidated financial statements. In March 2024, the FASB issued ASU No 2024-01, Compensation — Stock Compensation (Topic 718) — Scope Application of Profits Interest and Similar Awards (“ASU 2024-01”) in order to drive consistency across entities in their application of guidance to profits interest and similar types of award grants. ASU 2024-01 seeks to improve consistency through additional examples and illustrations. The guidance is applicable to all entities that account for profits interest awards as compensation to employees or nonemployees and the guidance to be added in paragraph 718-10-15-3 is applicable to all entities that enter into share-based payment transactions. For public business entities ASU 2024-01 is effective for annual periods beginning after December 15, 2024 and interim periods within those annual periods. The Company expects to adopt the standard for the fiscal year beginning December 30, 2024. The Company is currently evaluating the impact of its pending adoption of ASU 2024-01 on its consolidated financial statements.

Investment Securities (Tables)

Investment Securities (Tables)	3 Months Ended
	Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]
Summary of Available-for-sale Investment Securities	The following table summarizes the Company’s available-for-sale investment securities as of March 31, 2024: Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Allowance for Credit Losses Fair Value U.S. corporate bonds and U.S. dollar $ 24,047 $ 6 $ ( 329 ) $ — $ 23,724 Total $ 24,047 $ 6 $ ( 329 ) $ — $ 23,724 The following table summarizes the Company’s available-for-sale investment securities as of December 31, 2023: Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Allowance for Credit Losses Fair Value U.S. corporate bonds and U.S. dollar $ 33,134 $ 10 $ ( 477 ) $ — $ 32,667 Total $ 33,134 $ 10 $ ( 477 ) $ — $ 32,667
Summary of Contractual Maturities of Investment Securities	The amortized cost and fair value of the Company’s investments in available-for-sale securities as of March 31, 2024 by contractual maturity are as follows: Amortized Cost Fair Value Due within one year $ 19,064 $ 18,792 Due after one year through five years 4,983 4,932 Total available-for-sale $ 24,047 $ 23,724
Schedule of Unrealized Loss Aging for Available-for-sale Securities	The following tables present the Company ’s unrealized loss aging for available-for-sale securities by type and length of time the security was in a continuous unrealized loss position as of the periods presented: March 31, 2024 Less than 12 months 12 months or longer Total Fair Value Unrealized Losses Fair Value Unrealized Losses Fair Value Unrealized Losses U.S. corporate bonds and U.S. dollar $ 2,397 $ ( 10 ) $ 20,315 $ ( 319 ) $ 22,712 $ ( 329 ) Total $ 2,397 $ ( 10 ) $ 20,315 $ ( 319 ) $ 22,712 $ ( 329 ) December 31, 2023 Less than 12 months 12 months or longer Total Fair Value Unrealized Losses Fair Value Unrealized Losses Fair Value Unrealized Losses U.S. corporate bonds and U.S. dollar $ 699 $ ( 3 ) $ 29,247 $ ( 474 ) $ 29,946 $ ( 477 ) Total $ 699 $ ( 3 ) $ 29,247 $ ( 474 ) $ 29,946 $ ( 477 )

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule Of Notional Amounts of Outstanding Derivative Instruments	The following table presents the aggregated outstanding notional amounts related to the Company’s derivative financial instruments for the periods presented: Metric March 31, December 31, Commodity: Corn Bushels (in thousands) 1,629 2,351 Soybean Meal Tons 17 25

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Schedule of Financial Assets Measured at Fair Value	The following tables present information about the Company’s financial assets measured at fair value on a recurring basis for the periods presented: Fair Value Measurements as of March 31, 2024, Using: Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents: Money market $ 92,104 $ — $ — $ 92,104 Investment securities, available-for-sale: U.S. corporate bonds and U.S. dollar — 23,724 — 23,724 Prepaid expenses and other current assets: Derivative financial instruments — 93 — 93 Total assets measured at fair value $ 92,104 $ 23,817 $ — $ 115,921 Fair Value Measurements as of December 31, 2023, Using: Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents: Money market $ 64,498 $ — $ — $ 64,498 Investment securities, available-for-sale: U.S. corporate bonds and U.S. dollar — 32,667 — 32,667 U.S. Treasury — 394 — 394 Total assets measured at fair value $ 64,498 $ 33,061 $ — $ 97,559

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2024
Revenue from Contract with Customer [Abstract]
Summary of Net Revenue by Primary Product	The following table summarizes the Company’s net revenue by primary product for the periods presented: 13-Weeks Ended March 31, March 26, Net Revenue: Eggs and egg-related products $ 143,761 $ 112,790 Butter and butter-related products 4,168 6,382 Net Revenue $ 147,929 $ 119,172
Summary of Percentage of Net Revenue and Accounts Receivable, Net Due from Significant Customers	The percentage of net revenue from significant customers during the 13-week periods ended March 31, 2024 and March 26, 2023 is as follows: Net Revenue Net Revenue Customer A 24 % 25 % Customer B * * Customer C * * Customer D * * * Revenue was less than 10% As of March 31, 2024 and December 31, 2023, the Company had customers that individually exceeded 10% or more of the Company’s accounts receivable. The percentage of accounts receivable, net due from significant customers as of March 31, 2024 and December 31, 2023 is as follows: Accounts Receivable, Net as of March 31, 2024 Accounts Receivable, Net as of December 31, 2023 Customer A 20 % 18 % Customer B 12 % 12 % Customer C * 11 % Customer D 12 % 11 % * Accounts receivable, net was less than 10%

Allowance for Credit Losses (Ta

Allowance for Credit Losses (Tables)	3 Months Ended
	Mar. 31, 2024
Allowance for Credit Loss [Abstract]
Schedule of Changes in Allowance for Credit Losses	Changes in the allowance for credit losses for the 13-week period ended March 31, 2024 were as follows: Accounts Receivable Prepaid Expenses and other Current Assets Total As of December 31, 2023 $ ( 550 ) $ ( 227 ) $ ( 777 ) Provisions charged to operating results 284 ( 48 ) 236 Account write-offs — 140 140 As of March 31, 2024 $ ( 266 ) $ ( 135 ) $ ( 401 )

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2024
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consisted of the following as of the periods presented: March 31, December 31, Eggs and egg-related products $ 21,346 $ 25,521 Butter and butter-related products 5,084 1,697 Packaging 3,672 4,988 Pullets 221 289 Other 936 896 Reserve for inventory obsolescence ( 446 ) ( 496 ) Inventories $ 30,813 $ 32,895

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	3 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment consisted of the following as of the periods presented: March 31, December 31, Land $ 552 $ 552 Land improvements 818 818 Buildings and improvements 30,532 30,532 Vehicles 1,055 1,055 Machinery and equipment 54,355 50,979 Leasehold improvements 491 492 Furniture and fixtures 479 461 Construction in progress 2,211 3,001 90,493 87,890 Less: Accumulated depreciation and amortization ( 24,262 ) ( 21,051 ) Property, plant and equipment, net $ 66,231 $ 66,839

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Schedule of Components of Lease Cost	The components of lease cost, classified within cost of goods sold, selling, general and administrative and interest expense for the 13-week periods ended March 31, 2024 and March 26, 2023 are below: 13-Weeks Ended March 31, March 26, Operating lease cost $ 922 $ 361 Finance lease cost – amortization of right-of-use assets 914 447 Finance lease cost – interest on lease liabilities 246 132 Short-term lease cost 32 117 Variable lease cost 2,507 1,563 Variable lease cost – long-term supply contracts 25,340 43,086 Total lease cost $ 29,961 $ 45,706
Summary of Operating and Finance Leases Future Undiscounted Cash Flows	Future undiscounted cash flows are as follows: As of March 31, 2024 Operating Leases Finance Leases 2024 $ 4,227 $ 3,238 2025 3,234 4,356 2026 3,018 4,387 2027 — 3,611 2028 — — Thereafter — — Total lease payments 10,479 15,592 Less imputed interest ( 796 ) ( 1,792 ) Total present value of lease liabilities $ 9,683 $ 13,800

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consisted of the following as of the periods presented: March 31, December 31, Employee-related costs $ 4,788 $ 9,131 Promotions and customer deductions 6,858 6,982 Distribution fees and freight 3,087 2,876 Marketing and broker commissions 3,113 3,627 Purchases of inventory 2,000 525 Professional fees 2,108 1,066 Other 326 11 Accrued liabilities $ 22,280 $ 24,218

Common Stock (Tables)

Common Stock (Tables)	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Schedule of Reserved Shares of Common Stock for Issuance	As of each balance sheet date, the Company had reserved shares of common stock for issuance in connection with the following: March 31, December 31, Options to purchase common stock 3,722,192 5,123,860 Restricted stock units (“RSUs”) 725,611 675,029 Performance stock units (“PSUs”) 240,072 — Shares available for grant under the 2020 Equity Incentive 14,876,536 12,796,409 Total 19,564,411 18,595,298

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Summary of Recognized Stock - Based Compensation Expense	The Company recognized stock-based compensation expense in the condensed consolidated statements of operations for the periods presented: 13-Weeks Ended March 31, March 26, Cost of goods sold $ 47 $ 53 Selling, general and administrative expense 1,935 2,188 Total $ 1,982 $ 2,241
Summary of Stock Option Activity	The following table summarizes the Company’s stock option activity since December 31, 2023: Number of Weighted- Weighted- Aggregate Outstanding as of December 31, 2023 3,920,485 $ 10.07 $ 28,749 Granted — $ — Exercised ( 180,086 ) $ 4.57 $ 2,402 Cancelled/Forfeited ( 18,207 ) $ 22.45 $ 3 Outstanding as of March 31, 2024 3,722,192 $ 10.27 5.6 $ 50,127 Options exercisable as of March 31, 2024 2,895,661 $ 9.45 5.1 $ 41,438 Options vested and expected to vest as of March 31, 2024 3,722,192 $ 10.27 5.6 $ 50,127
Summary of RSU Activity	The following table summarizes the Company’s RSU activity since December 31, 2023: Number of Weighted- Unvested as of December 31, 2023 565,376 $ 14.24 Granted 377,352 $ 20.99 Vested 1 ( 201,702 ) $ 14.39 Forfeited ( 15,415 ) $ 15.08 Unvested as of March 31, 2024 725,611 $ 17.69 Includes 62,781 shares of common stock withheld to cover taxes on the release of vested RSUs, which became available for future grants pursuant
Summary of PSU activity	The following table summarizes the Company’s PSU activity since December 31, 2023: Number of Weighted- Unvested as of December 31, 2023 — Granted 240,072 $ 20.99 Unvested as of March 31, 2024 240,072 $ 20.99

Net Income Per Share (Tables)

Net Income Per Share (Tables)	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Income Per Share	Basic and diluted net income per share attributable to Vital Farms, Inc. common stockholders were calculated as follows: 13-Weeks Ended March 31, March 26, Numerator: Net income $ 19,023 $ 7,150 Denominator: Weighted average common shares outstanding — basic 41,792,527 40,764,546 Weighted average effect of potentially dilutive securities: Effect of potentially dilutive stock options 1,805,636 2,423,087 Effect of potentially dilutive restricted stock units 241,526 208,947 Effect of potentially dilutive common stock issuable pursuant to the ESPP 6,263 1,756 Weighted average common shares outstanding — diluted 43,845,952 43,398,336 Net income per share attributable to Vital Farms, Inc. stockholders Basic $ 0.46 $ 0.18 Diluted $ 0.43 $ 0.16
Schedule of Common Shares Excluded from Computation of Diluted Earnings Per Share	The Company excluded the following shares of common stock, outstanding at each period end, from the computation of diluted net income per share attributable to Vital Farms, Inc. common stockholders for the periods indicated because including them would have had an anti-dilutive effect: 13-Weeks Ended March 31, March 26, Options to purchase common stock 37,424 22,363 Unvested RSUs 17,533 704 Unvested PSUs 21,164 — 76,121 23,067

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income	The amounts reclassified from accumulated other comprehensive income (“AOCI”) to the unaudited consolidated statements of operations were as follows (in thousands): Amounts Reclassified from AOCI 13-Week Period Ended AOCI Component Statement of Income Classification March 31, March 26, Losses on available-for-sale securities Other expense, net $ ( 1 ) $ 34 Total before tax $ ( 1 ) 34 Tax benefit $ — ( 8 ) Net of tax $ ( 1 ) $ 26
Schedule of Component of Other Comprehensive Income	The gross amount and related tax (expense) benefit recorded in, and associated with, each component of other comprehensive income were as follows (in thousands): 13-Weeks Ended March 31, 2024 March 26, 2023 Before Tax Tax After Tax Before Tax Tax After Tax Available-for-sale debt securities: Unrealized net holding gain 144 $ ( 35 ) $ 109 $ 517 $ ( 122 ) $ 395 Amounts reclassified for realized losses to earnings ( 1 ) — ( 1 ) 34 ( 8 ) 26 Total other comprehensive income $ 143 $ ( 35 ) $ 108 $ 551 $ ( 130 ) $ 421

Nature of the Business and Ba_2

Nature of the Business and Basis of Presentation - Additional Information (Details)	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Date of incorporation	Jun. 06, 2013

Investment Securities - Summary

Investment Securities - Summary of Available-for-sale Investment Securities (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Schedule Of Available For Sale Securities [Line Items]
Total available-for-sale Amortized Cost	$ 24,047,000	$ 33,134,000
Unrealized Gains	6,000	10,000
Unrealized Losses	(329,000)	(477,000)
Allowance for Credit Losses	0	0
Fair Value	23,724,000	32,667,000
U.S. corporate bonds and U.S. dollar denominated foreign bonds
Schedule Of Available For Sale Securities [Line Items]
Total available-for-sale Amortized Cost	24,047,000	33,134,000
Unrealized Gains	6,000	10,000
Unrealized Losses	(329,000)	(477,000)
Allowance for Credit Losses	0	0
Fair Value	$ 23,724,000	$ 32,667,000

Investment Securities - Additio

Investment Securities - Additional Information (Details)	3 Months Ended
	Mar. 31, 2024 USD ($) Position Security	Mar. 26, 2023 USD ($)	Dec. 31, 2023 USD ($)
Schedule Of Available For Sale Securities [Line Items]
Proceeds from the sale of available-for-sale securities	$ 0	$ 0
Unrealized Losses	$ 329,000		$ 477,000
Unrealized Loss Position greater than 12 months | Position	35
Allowance for Credit Losses	$ 0		$ 0
Maximum
Schedule Of Available For Sale Securities [Line Items]
Unrealized Losses	$ 37,000
AFS Securities
Schedule Of Available For Sale Securities [Line Items]
Number of Securities Issuances for unrealized losses | Security	38

Investment Securities - Summa_2

Investment Securities - Summary of Contractual Maturities of Investment Securities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Due within one year Amortized Cost	$ 19,064
Due after one year through five years Amortized Cost	4,983
Total available-for-sale Amortized Cost	24,047	$ 33,134
Due within one year Fair Value	18,792
Due after one year through five years Fair Value	4,932
Total available-for-sale Fair Value	$ 23,724	$ 32,667

Investment Securities - Schedul

Investment Securities - Schedule of Unrealized Loss Aging for Available-for-sale Securities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Schedule Of Available For Sale Securities [Line Items]
Fair value, less than 12 months	$ 2,397	$ 699
Unrealized losses, less than 12 months	(10)	(3)
Fair value, 12 months or longer	20,315	29,247
Unrealized losses, 12 months or longer	(319)	(474)
Fair value, Total	22,712	29,946
Unrealized losses, Total	(329)	(477)
U.S. corporate bonds and U.S. dollar denominated foreign bonds
Schedule Of Available For Sale Securities [Line Items]
Fair value, less than 12 months	2,397	699
Unrealized losses, less than 12 months	(10)	(3)
Fair value, 12 months or longer	20,315	29,247
Unrealized losses, 12 months or longer	(319)	(474)
Fair value, Total	22,712	29,946
Unrealized losses, Total	$ (329)	$ (477)

Derivative Financial Instrume_3

Derivative Financial Instruments - Schedule Of Notional Amounts of Outstanding Derivative Instruments (Details) bu in Thousands, Bushels in Thousands	Mar. 31, 2024 bu T	Dec. 31, 2023 Bushels T
Corn
Derivative [Line Items]
Notional amounts of derivative financial instruments	1,629	2,351
Soybean Meal
Derivative [Line Items]
Notional amounts of derivative financial instruments	17	25

Derivative Financial Instrume_4

Derivative Financial Instruments - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 26, 2023
Derivative Instruments, Gain (Loss) [Line Items]
Pre-tax amount of derivative losses	$ (300)	$ (1,047)
Commodity Contract [Member] | Non designated [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Pre-tax amount of derivative losses	$ 300	$ 1,415

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value (Details) - Recurring - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Assets measured at fair value	$ 115,921	$ 97,559
Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Assets measured at fair value	92,104	64,498
Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Assets measured at fair value	23,817	33,061
Money market
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Assets measured at fair value	92,104	64,498
Money market | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Assets measured at fair value	92,104	64,498
U.S. corporate bonds and U.S. dollar denominated foreign bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Assets measured at fair value	23,724	32,667
U.S. corporate bonds and U.S. dollar denominated foreign bonds | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Assets measured at fair value	23,724	32,667
U.S. Treasury
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Assets measured at fair value		394
U.S. Treasury | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Assets measured at fair value		$ 394
Derivative financial instruments
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Assets measured at fair value	93
Derivative financial instruments | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Assets measured at fair value	$ 93

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details)	Mar. 31, 2024 USD ($)
Fair Value Disclosures [Abstract]
Fair value liabilities transfers, Level 2 to Level 1	$ 0

Revenue Recognition - Summary o

Revenue Recognition - Summary of Net Revenue by Primary Product (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 26, 2023
Disaggregation Of Revenue [Line Items]
Net revenue	$ 147,929	$ 119,172
Eggs and Egg Related Products
Disaggregation Of Revenue [Line Items]
Net revenue	143,761	112,790
Butter and Butter Related Products
Disaggregation Of Revenue [Line Items]
Net revenue	$ 4,168	$ 6,382

Revenue Recognition - Summary_2

Revenue Recognition - Summary of Percentage of Net Revenue from Significant Customers (Details)	3 Months Ended
	Mar. 31, 2024	Mar. 26, 2023
Customer Concentration Risk | Net Revenue | Customer A
Disaggregation Of Revenue [Line Items]
Concentration risk percentage	24%	25%

Revenue Recognition - Summary_3

Revenue Recognition - Summary of Percentage of Accounts Receivable, Net Due from Significant Customers (Details) - Customer Concentration Risk - Accounts Receivable	3 Months Ended
	Mar. 31, 2024	Mar. 26, 2023
Customer A
Disaggregation Of Revenue [Line Items]
Concentration risk percentage	20%	18%
Customer B
Disaggregation Of Revenue [Line Items]
Concentration risk percentage	12%	12%
Customer C
Disaggregation Of Revenue [Line Items]
Concentration risk percentage		11%
Customer D
Disaggregation Of Revenue [Line Items]
Concentration risk percentage	12%	11%

Allowance for Credit Losses - A

Allowance for Credit Losses - Additional Information (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Allowance for Credit Loss [Abstract]
Allowance for credit losses	$ 401	$ 777

Allowance for Credit Losses - S

Allowance for Credit Losses - Schedule of Changes in Allowance for Credit Losses (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($)
Financing Receivable, Allowance for Credit Loss [Line Items]
Allowance for credit losses, Beginning balance	$ (777)
Provisions charged to operating results	236
Account write-off	140
Allowance for credit losses,Ending balance	(401)
Trade Receivable [Member]
Financing Receivable, Allowance for Credit Loss [Line Items]
Allowance for credit losses, Beginning balance	(550)
Provisions charged to operating results	284
Account write-off	0
Allowance for credit losses,Ending balance	(266)
Prepaid Expenses and other Current Assets [Member]
Financing Receivable, Allowance for Credit Loss [Line Items]
Allowance for credit losses, Beginning balance	(227)
Provisions charged to operating results	(48)
Account write-off	140
Allowance for credit losses,Ending balance	$ (135)

Inventories - Schedule of Inven

Inventories - Schedule of Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Inventory [Line Items]
Reserve for inventory obsolescence	$ (446)	$ (496)
Inventories	30,813	32,895
Eggs and Egg Related Products
Inventory [Line Items]
Inventory gross	21,346	25,521
Butter and Butter Related Products
Inventory [Line Items]
Inventory gross	5,084	1,697
Packaging
Inventory [Line Items]
Inventory gross	3,672	4,988
Pullets
Inventory [Line Items]
Inventory gross	221	289
Other
Inventory [Line Items]
Inventory gross	$ 936	$ 896

Property, Plant and Equipment -

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 90,493	$ 87,890
Less: Accumulated depreciation and amortization	(24,262)	(21,051)
Property, plant and equipment, net	66,231	66,839
Land
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	552	552
Land improvements
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	818	818
Buildings and Improvements
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	30,532	30,532
Vehicles
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	1,055	1,055
Machinery and Equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	54,355	50,979
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	491	492
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	479	461
Construction in Progress
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 2,211	$ 3,001

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 26, 2023
Property Plant And Equipment [Line Items]
Depreciation and amortization of property, plant and equipment	$ 2,297	$ 1,693

Leases - Schedule of Components

Leases - Schedule of Components of Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 26, 2023
Leases [Abstract]
Operating lease cost	$ 922	$ 361
Finance lease cost - amortization of right-of-use assets	914	447
Finance lease cost - interest on lease liabilities	246	132
Short-term lease cost	32	117
Variable lease cost	2,507	1,563
Variable lease cost - long-term supply contracts	25,340	43,086
Total lease cost	$ 29,961	$ 45,706

Leases - Summary of Operating a

Leases - Summary of Operating and Finance Leases Future Undiscounted Cash Flows (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Leases [Abstract]
Operating leases 2024	$ 4,227
Operating leases 2025	3,234
Operating leases 2026	3,018
Operating leases 2027	0
Operating leases 2028	0
Operating leases Thereafter	0
Total lease payments	10,479
Less imputed interest	(796)
Total present value of lease liabilities	9,683
Finance leases 2024	3,238
Finance leases 2025	4,356
Finance leases 2026	4,387
Finance leases 2027	3,611
Finance leases 2028	0
Finance leases Thereafter	0
Total lease payments	15,592
Less imputed interest	(1,792)
Total present value of lease liabilities	$ 13,800

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 26, 2023
Leases [Abstract]
ROU assets obtained in exchange for new finance lease obligations	$ 907	$ 4
ROU assets obtained in exchange for new operating lease obligations	$ 2,489	$ 0

Accrued Liabilities - Schedule

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Employee-related costs	$ 4,788	$ 9,131
Promotions and customer deductions	6,858	6,982
Distribution fees and freight	3,087	2,876
Marketing and broker commissions	3,113	3,627
Purchases of inventory	2,000	525
Professional fees	2,108	1,066
Other	326	11
Accrued liabilities	$ 22,280	$ 24,218

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Details) - USD ($)		3 Months Ended		9 Months Ended
	Apr. 09, 2024	Mar. 31, 2024	Mar. 26, 2023	Sep. 24, 2023	Oct. 31, 2017
Revolving Line of Credit
Debt Instrument [Line Items]
Proceeds from borrowing under revolving line of credit		$ 0	$ 7,500,000
Repayment of revolving line of credit		0	7,500,000
Outstanding Debt		0
Interest expense		0	$ 7,000
PNC Bank, National Association | Revolving Line of Credit
Debt Instrument [Line Items]
Line of credit facility maximum borrowing capacity					$ 10,000,000
PNC Bank, National Association | Revolving Line of Credit | Sixth Amendment
Debt Instrument [Line Items]
Line of credit facility maximum borrowing capacity		$ 20,000,000
PNC Bank, National Association | Revolving Line of Credit | Tenth Amendment | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate
Debt Instrument [Line Items]
Debt instrument basis spread on variable rate		2%
PNC Bank, National Association | Revolving Line of Credit | Tenth Amendment | Alternate Base Rate
Debt Instrument [Line Items]
Debt instrument basis spread on variable rate		1%
PNC Bank, National Association | Term Loan
Debt Instrument [Line Items]
Debt instrument face amount					4,700,000
PNC Bank, National Association | Equipment Loan
Debt Instrument [Line Items]
Line of credit facility maximum borrowing capacity					$ 1,500,000
PNC Bank, National Association | Credit Facility
Debt Instrument [Line Items]
Line of credit facility covenant terms		The PNC Credit Facility was secured by all of the Company’s assets (other than real property and certain other property excluded pursuant to the terms of the PNC Credit Facility) and required the Company to maintain three financial covenants: a fixed charge coverage ratio, a leverage ratio and a minimum tangible net worth requirement. The PNC Credit Facility also contained various covenants relating to limitations on indebtedness, acquisitions, mergers, consolidations and the sale of properties and liens.
Line of credit facility covenant compliance		As of March 31, 2024, the Company was in compliance with all covenants under the PNC Credit Facility.
PNC Bank, National Association | Credit Facility | Eleventh Amendment
Debt Instrument [Line Items]
Maturity of long term debt				Apr. 02, 2025
PNC Bank, National Association | Credit Facility | Term Loan And Equipment Loan
Debt Instrument [Line Items]
Debt instrument eliminated				2021-04
JP Morgan Chase Bank NA | Revolving Line of Credit | Subsequent Event
Debt Instrument [Line Items]
Line of credit facility maximum borrowing capacity	$ 60,000,000
JPMorgan Credit Facility | Subsequent Event
Debt Instrument [Line Items]
Debt instrument face amount	$ 35,000,000
Percentage of debt instrument face amount	100%
Letter of credit sub-limit	$ 5,000,000
Revolving credit facility interest rate description	Any borrowings under the JPMorgan Credit Facility bear interest, at the Company’s election, at either (i) an adjusted term Secured Overnight Financing Rate or adjusted daily Secured Overnight Financing Rate plus 0.10% plus a margin of either 0.75%, 1.00% or 1.25% depending on the Company’s net leverage ratio, or (ii) an alternative base rate plus a margin or either 1.75%, 2.00% or 2.25%, depending on the Company’s net leverage ratio. The Company is required to pay a commitment fee on the undrawn portion of the aggregate commitments that accrues at either 0.20% or 0.375% per annum depending on the Company’s revolving exposure.
Leverage ratio	3.25%
Increase in leverage ratio	4%
Minimum fixed charge coverage ratio	1.35%
JPMorgan Credit Facility | Subsequent Event | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate
Debt Instrument [Line Items]
Debt instrument basis spread on variable rate	0.10%

Common Stock - Additional Infor

Common Stock - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Class Of Stock [Line Items]
Common stock, shares authorized	310,000,000	310,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares issued	42,003,656	41,684,649
Common stock, shares outstanding	42,003,656	41,684,649
Common stock voting rights	Each share of the Company’s common stock is entitled to one vote on all matters submitted to a vote of the Company’s stockholders.
Common stock dividend declared or paid	$ 0

Common Stock - Schedule of Rese

Common Stock - Schedule of Reserved Shares of Common Stock for Issuance (Details) - shares	Mar. 31, 2024	Dec. 31, 2023
Class Of Stock [Line Items]
Common stock for issuance	19,564,411	18,595,298
Employee Stock Option
Class Of Stock [Line Items]
Common stock for issuance	3,722,192	5,123,860
RSUs
Class Of Stock [Line Items]
Common stock for issuance	725,611	675,029
PSUs
Class Of Stock [Line Items]
Common stock for issuance	240,072
Shares Available for Grant | 2020 Equity Incentive Plan and 2020 Employee Stock Purchase Plan
Class Of Stock [Line Items]
Common stock for issuance	14,876,536	12,796,409

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ in Thousands			1 Months Ended	3 Months Ended
		Jan. 01, 2024	Jul. 31, 2020	Mar. 31, 2024	Mar. 26, 2023	Dec. 31, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock for issuance				19,564,411		18,595,298
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense				$ 2,539
Fair value of shares vested				$ 1,660	$ 1,015
Expected weighted-average period of recognition				1 year 6 months 14 days
Stock options - vest year				3 years
Stock options - date of grant and expire				10 years
Common stock for issuance				3,722,192		5,123,860
RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense				$ 11,919
Fair value of shares vested				$ 2,903	1,655
Vested	[1]			(201,702)
Expected weighted-average period of recognition				2 years 5 months 15 days
Stock options - vest year				3 years
Common stock for issuance				725,611		675,029
PSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense				$ 9,871
Fair value of shares vested				$ 0	$ 0
Vested				0	0
Expected weighted-average period of recognition				2 years 8 months 26 days
Stock options - vest year				3 years
Common stock for issuance				240,072
PSUs | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of number of shares earned				200%
PSUs | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of number of shares earned				0%
2020 Equity Incentive Plan | Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum number of shares issuable			8,595,871
Percentage of outstanding common stock			4%
Share-based compensation award, description				Initially, the maximum number of the Company’s common stock that may be issued under the 2020 Incentive Plan was 8,595,871 shares. The 2020 Incentive Plan provides that the number of shares reserved and available for issuance under the 2020 Incentive Plan will automatically increase each January 1, beginning on January 1, 2021 and ending on (and including) January 1, 2030, by an amount equal to 4% of the outstanding number of shares of common stock on the immediately preceding December 31 or such lesser number of shares as determined by the Company’s Board of Directors.
Number of shares available for future grants				12,347,296
Number of new shares issued		1,667,385
2020 Employee Stock Purchase Plan | Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum number of shares issuable			900,000
Percentage of outstanding common stock			1%
Share-based compensation award, description				The 2020 ESPP authorizes the initial issuance of up to 900,000 shares of the Company’s common stock to eligible employees of the Company or, as designated by the Company’s Board of Directors, employees of a related company. The 2020 ESPP provides that the number of shares reserved and available for issuance under the 2020 ESPP will automatically increase each January 1, beginning on January 1, 2021 and ending on (and including) January 1, 2030, by an amount equal to the lesser of (i) 1% of the outstanding number of shares of common stock on the immediately preceding December 31 and (ii) 900,000, or such lesser number of shares as determined by the Company’s Board of Directors.
Number of new shares issued		416,846
Common stock for issuance				2,529,240
[1] Includes 62,781 shares of common stock withheld to cover taxes on the release of vested RSUs, which became available for future grants pursuant

Stock-Based Compensation -Summa

Stock-Based Compensation -Summary of Recognized Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 26, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense	$ 1,982	$ 2,241
Cost of Goods Sold
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense	47	53
Selling, General and Administrative
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense	$ 1,935	$ 2,188

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($) $ / shares shares
Share-Based Payment Arrangement [Abstract]
Number of Options, Beginning balance | shares	3,920,485
Number of Options, Granted | shares	0
Number of Options, Exercised | shares	(180,086)
Number of Options, Cancelled | shares	(18,207)
Number of Options, Ending balance | shares	3,722,192
Number of Options, Options exercisable as of March 31, 2024 | shares	2,895,661
Number of Options, Options vested and expected to vest as of March 31, 2024 | shares	3,722,192
Weighted-Average Exercise Price, Beginning balance | $ / shares	$ 10.07
Weighted-Average Exercise Price, Options Granted | $ / shares	0
Weighted-Average Exercise Price, Options Exercised | $ / shares	4.57
Weighted-Average Exercise Price, Options Cancelled | $ / shares	22.45
Weighted-Average Exercise Price, Ending balance | $ / shares	10.27
Weighted-Average Exercise Price, Options exercisable as of March 31, 2024 | $ / shares	9.45
Weighted-Average Exercise Price, Options vested and expected to vest as of March 31, 2024 | $ / shares	$ 10.27
Weighted Average Remaining Contractual Life (Years), Balance	5 years 7 months 6 days
Weighted Average Remaining Contractual Life (Years), Options exercisable as of March 31, 2024	5 years 1 month 6 days
Weighted Average Remaining Contractual Life (Years), Options vested and expected to vest as of March 31, 2024	5 years 7 months 6 days
Aggregate Intrinsic Value, Beginning balance | $	$ 28,749
Aggregate Intrinsic Value, Exercised | $	2,402
Aggregate Intrinsic Value, Cancelled | $	3
Aggregate Intrinsic Value, Ending balance | $	50,127
Aggregate Intrinsic Value, Options exercisable as of March 31, 2024 | $	41,438
Aggregate Intrinsic Value, Options vested and expected to vest as of March 31, 2024 | $	$ 50,127

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of RSU Activity (Details) - RSUs	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested as of December 31, 2023 | shares	565,376
Granted | shares	377,352
Vested | shares	(201,702)	[1]
Forfeited | shares	(15,415)
Unvested as of March 31, 2024 | shares	725,611
Weighted-Average Grant Date Fair Value, Beginning balance | $ / shares	$ 14.24
Weighted-Average Grant Date Fair Value, Granted | $ / shares	20.99
Weighted-Average Grant Date Fair Value, Vested | $ / shares	14.39	[1]
Weighted-Average Grant Date Fair Value, Forfeited | $ / shares	15.08
Weighted-Average Grant Date Fair Value, Ending balance | $ / shares	$ 17.69
[1] Includes 62,781 shares of common stock withheld to cover taxes on the release of vested RSUs, which became available for future grants pursuant

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of RSU Activity (Parenthetical) (Details)	9 Months Ended
	Sep. 24, 2023 shares
RSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares of common stock withheld to cover taxes	62,781

Stock-Based Compensation - Su_4

Stock-Based Compensation - Summary of PSU Activity (Details) - PSUs	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unvested as of December 31, 2023	0
Granted	240,072
Unvested as of March 31, 2024	240,072
Weighted-Average Grant Date Fair Value, Granted | $ / shares	$ 20.99
Weighted-Average Grant Date Fair Value, Ending balance | $ / shares	$ 20.99

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details)	3 Months Ended
	Mar. 31, 2024	Mar. 26, 2023
Income Tax Disclosure [Abstract]
Effective tax rate	23%	26%

Net Income Per Share - Schedule

Net Income Per Share - Schedule of Basic and Diluted Net Income Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 26, 2023
Numerator:
Net income	$ 19,023	$ 7,150
Denominator:
Weighted average common shares outstanding — basic	41,792,527	40,764,546
Weighted average effect of potentially dilutive securities:
Weighted average common shares outstanding — diluted	43,845,952	43,398,336
Net income (loss) per share attributable to Vital Farms, Inc. stockholders
Basic	$ 0.46	$ 0.18
Diluted	$ 0.43	$ 0.16
Employee Stock Option
Weighted average effect of potentially dilutive securities:
Effect of potentially dilutive stock options	1,805,636	2,423,087
RSUs
Weighted average effect of potentially dilutive securities:
Effect of potentially dilutive stock options	241,526	208,947
Employee Stock Purchase Plan
Weighted average effect of potentially dilutive securities:
Effect of potentially dilutive stock options	6,263	1,756

Net Income Per Share - Schedu_2

Net Income Per Share - Schedule of Excluded Common Shares Including at Anti-dilutive Effect (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 26, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	76,121	23,067
Options to Purchase Common Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	37,424	22,363
Unvested RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	17,533	704
Unvested PSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	21,164

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income - Schedule of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 26, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amounts reclassified from accumulated other comprehensive loss to earnings	$ (1)	$ 34
Tax (expense) benefit	0	(8)
Net of tax	(1)	26
Gains (Losses) on available-for-sale securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amounts reclassified from accumulated other comprehensive loss to earnings	$ (1)	$ 34

Accumulated Other Comprehensi_4

Accumulated Other Comprehensive Income - Schedule of Component of Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 26, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Unrealized net holding gain, Before Tax	$ 144	$ 517
Unrealized net holding gain, Tax	(35)	(122)
Unrealized net holding gain, After Tax	109	395
Amounts reclassified from accumulated other comprehensive loss to earnings	(1)	34
Amounts reclassified for realized losses to earnings	0	(8)
Net of tax	(1)	26
Other Comprehensive Income (Loss), Tax, Total	35	130
Other comprehensive income, net of tax	108	421
Other comprehensive income, before tax	143	551
Available-for-Sale Debt Securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amounts reclassified from accumulated other comprehensive loss to earnings	$ (1)	$ 34

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Long-term supply contracts costs	$ 200,000
Contract cost paid	1,200
Contract cost payable	$ 1,800

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - Sandpebble Builders Preconstruction, Inc - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 26, 2023
Related Party Transaction [Line Items]
Expense paid to related party	$ 248	$ 116
Amounts owed to related party	$ 313	$ 373

Subsequent Event - Additional I

Subsequent Event - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Apr. 09, 2024
Subsequent Event [Line Items]
Monthly payment	$ 10,000
Restated Employment Agreement Description	18 months of his annual base salary over the 18-month period following the departure date
Subsequent Event | Revolving Line of Credit | JP Morgan Chase Bank NA
Subsequent Event [Line Items]
Line of credit facility maximum borrowing capacity		$ 60,000